hotspot -WSS

hotspot

author：focus 2025-09-02 08:14:54 - browse：5

James Comer (R-KY) walks on the House side of the U.S. Capitol on May 14, 2024 in Washington, DC — Rep. James Comer (R-Ky.), the chair of the House Committee on Oversight and Accountability, has taken an interest in pharmacy benefit managers. Kent Nishimura/Getty Images

WASHINGTON — Executives from the three major pharmacy benefit manager companies have been invited to testify before the House Committee on Oversight and Accountability next month, four sources familiar with the planning told STAT.

Executives from Optum, CVS Caremark, and Express Scripts, owned by Cigna, were asked to testify before the panel on June 4.

The committee and companies did not respond to requests for comment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Liquid biopsy for lung cancer is launched by Delfi

focus

WSS

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Psychedelics group wrestles with new pharma identity

Physician executives need more than on

What to expect at HLTH 2023, the health care industry conference

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

In Memoriam: Notable people who died in 2023

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Cancer drug shortages should be causing more outrage

Histogen: Failed biotech offers rare public look inside

Alkermes shareholders re

Phenylephrine and the overlooked value of the placebo effect

After affirmative action ruling, medical educators look to 'holistic review'

Chan Zuckerberg Biohub Chicago to focus on inflammation

Malaria cases in Florida and Texas: Here’s what you need to know

United colonoscopy coverage change 'may cost lives,' doctors say

After affirmative action ruling, medical educators look to 'holistic review'

Was Amgen transparent enough on FDA's concern on cancer drug?

explore

Physician executives need more than on

Chemotherapy drug shortage eases slightly but still widespread

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Alkermes shareholders re

3 questions for the future of Biden's cancer moonshot

Jerome Adams on the need for new antivirals for Covid

knowledge

hotspot

focus

focus